###begin article-title 0
MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon
###end article-title 0
###begin p 1
To whom correspondence should be addressed at present address: Department of Surgery, University of Liverpool, 5th Floor UCD, Daulby Street, Liverpool L69 3GA, UK. Tel: +44 151 706 4185; Fax: +44 151 706 5826; Email: mboyd@liverpool.ac.uk Present addresses: Nikolina Vlatkovic, University of Liverpool, Liverpool L69 3GA, UK Stephanie Guerrera, SmithKline-Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Ying Li, Genetech, South San Francisco, CA 94080, USA Dale S. Haines, The Fels Institute for Cancer Research and Molecular Biology, Philadelphia, PA 19140, USA
###end p 1
###begin p 2
###xml 461 469 449 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 168 173 <span type="species:ncbi:4932">yeast</span>
###xml 448 453 <span type="species:ncbi:4932">yeast</span>
###xml 545 550 <span type="species:ncbi:10090">mouse</span>
###xml 555 560 <span type="species:ncbi:9606">human</span>
###xml 596 601 <span type="species:ncbi:9606">human</span>
MDM2 is induced by p53 in response to cellular insults such as DNA damage and can have effects upon the cell cycle that are independent or downstream of p53. We used a yeast two-hybrid screen to identify proteins that bind to MDM2 and which therefore might be involved in these effects. We found that MDM2 can bind to the C-terminus of the catalytic subunit of DNA polymerase epsilon (DNA pol epsilon), to a region that is known to be essential in yeast. In an in vitro system we confirmed that MDM2 could bind to the homologous regions of both mouse and human DNA pol epsilon and to full-length human DNA pol epsilon. DNA pol epsilon co-immunoprecipitated with MDM2 from transfected H1299 cells and also from a HeLa cell nuclear extract. We show here that the DNA pol epsilon-interacting domain of MDM2 is located between amino acids 50 and 166. Our studies provide evidence that MDM2 interacts with a region of DNA pol epsilon that plays a critical role in the function of DNA pol epsilon.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c1">1</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c2">2</xref>
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c3">3</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c2">2</xref>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c3">3</xref>
###xml 453 456 453 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS</italic>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c2">2</xref>
###xml 655 659 655 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c4">4</xref>
###xml 805 806 805 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c5">5</xref>
###xml 807 808 807 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c6">6</xref>
###xml 868 869 868 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c5">5</xref>
###xml 937 938 937 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c5">5</xref>
###xml 939 940 939 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c7">7</xref>
###xml 962 963 962 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c8">8</xref>
###xml 964 965 964 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c9">9</xref>
###xml 999 1000 999 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c8">8</xref>
###xml 1001 1002 1001 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c9">9</xref>
###xml 1167 1169 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c10">10</xref>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c12">12</xref>
###xml 1280 1287 1280 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in&#160;vivo</italic>
###xml 1316 1319 1316 1319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 1367 1371 1367 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 1391 1393 1391 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c13">13</xref>
###xml 359 368 <span type="species:ncbi:10090">nude mice</span>
###xml 397 400 <span type="species:ncbi:10116">rat</span>
###xml 543 548 <span type="species:ncbi:9606">human</span>
###xml 1194 1199 <span type="species:ncbi:9606">human</span>
MDM2 was originally discovered as one of three genes amplified on double minute chromosomes in a tumourigenic derivative of NIH 3T3 cells (1) and it was later shown that MDM2 has oncogenic potential when overexpressed (2,3). High level expression of MDM2 has also been shown to confer tumourigenic potential upon non-transformed rodent fibroblasts in athymic nude mice (2,3). MDM2 can immortalise rat embryo fibroblasts and can cooperate with activated RAS to transform these cells (2). Elevated levels of MDM2 have been found in a variety of human tumours, most notably in soft tissue sarcomas where 20% of primary tumours contain multiple copies of the MDM2 gene (4). One mechanism by which MDM2 overexpression may lead to tumour development is through its ability to bind to the p53 tumour suppressor (5,6) and block the transcriptional activation function of p53 (5). MDM2 overexpression has been shown to block the transactivation (5,7), cell cycle arrest (8,9) and apoptotic functions of p53 (8,9). In addition, it has been shown that MDM2 regulates the stability of p53 by inducing ubiquitination and thus targeting the protein for degradation by proteosomes (10-12). Studies of primary human tumours have reinforced the idea that MDM2 overexpression inhibits p53 function in vivo. It has been shown that the p53 gene is rarely mutated in tumours in which the MDM2 gene is amplified (13).
###end p 4
###begin p 5
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c14">14</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c15">15</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c15">15</xref>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 470 474 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 479 482 479 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c16">16</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c17">17</xref>
###xml 337 341 <span type="species:ncbi:10090">Mice</span>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
MDM2 is itself a transcriptional target of p53 and induction of p53 transcriptional activity leads to increases in MDM2 mRNA and MDM2 protein (14,15). Thus an autoregulatory feedback loop (15) exists between these two proteins. The importance of the MDM2-p53 autoregulatory feedback loop has been confirmed by transgenic animal studies. Mice that possess a homozygous deletion of MDM2 die by day 7 of embryogenesis, whereas mice that possess homozygous deletion of both MDM2 and p53 are viable and develop normally (16,17). These results demonstrate that a primary function of MDM2 during development is to regulate p53 function.
###end p 5
###begin p 6
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c18">18</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c19">19</xref>
###xml 343 346 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF</sup>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c20">20</xref>
###xml 369 373 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 379 382 379 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c21">21</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c22">22</xref>
###xml 708 710 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c23">23</xref>
###xml 804 807 798 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 817 822 811 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F-1</italic>
###xml 834 841 828 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 843 845 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c24">24</xref>
###xml 851 854 845 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 952 955 946 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 996 998 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c25">25</xref>
###xml 860 875 <span type="species:ncbi:10090">transgenic mice</span>
###xml 961 965 <span type="species:ncbi:10090">mice</span>
###xml 1209 1214 <span type="species:ncbi:4932">yeast</span>
Notwithstanding the critical role MDM2 plays in regulating p53, there is good evidence that high levels of MDM2 alter cellular growth control pathways in a p53-independent manner. For example, MDM2 has been shown to interact with a number of additional growth control molecules, namely RB (18), the E2F-1/DP1 transcription complex (19) and p19ARF (20). Transfection of MDM2 into p53 null cells can alter the growth properties of these cells (21) and MDM2 isoforms that cannot bind to p53 retain the ability to transform NIH 3T3 cells (22). Moreover, MDM2 overexpression can block the growth inhibitory activities of transforming growth factor beta1 (TGF-beta1) in a p53-independent manner in cultured cells (23). Overexpression of MDM2 has been shown to induce uncoupling of S phase from mitosis in both p53 null and E2F-1 null cells in vivo (24) and p53 null transgenic mice that overexpress MDM2 develop a different spectrum of tumours compared with p53 null mice that do not overexpress MDM2 (25). Taken together these results suggest that MDM2 overexpression can, independent of the interaction with p53, alter cell growth control. In an effort to identify how MDM2 may mediate its effects we have used a yeast two-hybrid screen to identify novel MDM2-binding proteins that may shed some light upon the underlying pathways responsible for these effects.
###end p 6
###begin p 7
###xml 197 199 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c26">26</xref>
###xml 200 202 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c27">27</xref>
###xml 296 298 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c27">27</xref>
###xml 299 301 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c28">28</xref>
###xml 316 318 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c29">29</xref>
###xml 319 321 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c32">32</xref>
###xml 372 374 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c33">33</xref>
###xml 401 403 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c34">34</xref>
###xml 404 406 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c35">35</xref>
###xml 592 600 562 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 602 604 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c36">36</xref>
###xml 661 663 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c37">37</xref>
###xml 829 831 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c38">38</xref>
###xml 182 195 <span type="species:ncbi:4896">fission yeast</span>
###xml 339 344 <span type="species:ncbi:4932">yeast</span>
###xml 357 370 <span type="species:ncbi:4896">fission yeast</span>
###xml 579 584 <span type="species:ncbi:9606">human</span>
###xml 654 659 <span type="species:ncbi:4932">yeast</span>
###xml 812 817 <span type="species:ncbi:4932">yeast</span>
###xml 824 827 <span type="species:ncbi:9606">man</span>
We have found that MDM2 can bind to the C-terminus of the catalytic subunit of DNA polymerase epsilon (DNA pol epsilon). DNA pol epsilon is an essential molecule in both budding and fission yeast (26,27) and is thought to be involved in a number of cellular processes, including DNA replication (27,28), DNA repair (29-32) and, in budding yeast (but not in fission yeast; 33), the S phase checkpoint (34,35). The MDM2-binding domain on DNA pol epsilon was found to be located within a region of DNA pol epsilon (the C-terminus) that is not required for catalytic activity of the human enzyme in vitro (36) but which is essential for viability in budding yeast (37). Although this region of DNA pol epsilon has not yet been shown to play a role in these processes in multicellular organisms, it is conserved from yeast up to man (38). Our studies provide evidence that MDM2 interacts with a region of DNA pol epsilon that plays a critical role in the function of DNA pol epsilon.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Plasmids and antibodies
###end title 9
###begin p 10
###xml 365 368 341 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 439 442 415 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 523 526 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 529 532 505 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 567 570 543 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sma</italic>
###xml 908 911 872 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 918 921 882 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 1084 1086 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c39">39</xref>
###xml 1097 1100 1061 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 1109 1112 1073 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 1473 1476 1419 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 1483 1486 1429 1432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 1749 1752 1677 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 1755 1758 1683 1686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 1796 1799 1724 1727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 2160 2163 2058 2061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 2169 2172 2067 2070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sal</italic>
###xml 2235 2243 2127 2135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 2355 2358 2235 2238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 2429 2432 2303 2306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 2521 2524 2395 2398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 2571 2574 2445 2448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 2579 2582 2453 2456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 2613 2616 2487 2490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 2625 2628 2499 2502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
###xml 175 180 <span type="species:ncbi:9606">human</span>
###xml 287 293 <span type="species:ncbi:10090">murine</span>
###xml 505 511 <span type="species:ncbi:10090">murine</span>
###xml 600 606 <span type="species:ncbi:10090">murine</span>
###xml 1026 1044 <span type="species:ncbi:12285">black beetle virus</span>
###xml 1153 1158 <span type="species:ncbi:9606">human</span>
###xml 1607 1612 <span type="species:ncbi:9606">human</span>
###xml 1648 1651 <span type="species:ncbi:12285?0.4375">BBV</span>
###xml 1678 1684 <span type="species:ncbi:10090">murine</span>
###xml 1828 1833 <span type="species:ncbi:9606">human</span>
###xml 2112 2117 <span type="species:ncbi:9606">human</span>
###xml 2538 2541 <span type="species:ncbi:12285?0.4375">BBV</span>
pGAL4-DBD-MDM2 encodes full-length mouse MDM2 cloned in-frame with the GAL4-DNA-binding domain (DBD) and pGAL4-AD-DNA pol epsilon encodes nt 5833-6984 (numbering based on the human cDNA sequence, GenBank accession no. L09561) plus approximately500 bases of the 3'-untranslated region of murine DNA pol epsilon as a GAL4 activation domain (AD) fusion protein in the XhoI site of pACT (Clontech). pGAL4-AD-p53 encodes full-length p53 in the XhoI site of pACT. pQE32-MDM2 was prepared by cloning full-length murine MDM2 as an EcoRV-XhoI fragment from pBBV-MDM2 into the SmaI site of pQE32 (Qiagen). The murine C-terminal fragment of DNA pol epsilon was prepared by PCR amplification from pGAL4AD-DNA pol epsilon using oligonucleotides GAD5 (5'-gag aga gat atc gcc aat ttt aat caa agt ggg aat att-3') and GAD3 (5'-gag aga gcg gcc gct ttc agt atc tac gat tca tag atc tc-3') followed by restriction digestion with EcoRV and NotI and cloning into these sites in pBBV. pBBV was prepared by inserting an oligonucleotide containing the black beetle virus ribosomal binding sequences from pBD7 (39) into the HindIII and EcoRV sites of pcDNAI/Neo (Invitrogen). The human C-terminal fragment of DNA pol epsilon was made from cDNA prepared from MCF-7 cells (ATCC clone HTB 22) by amplification with oligonucleotides DNA pol epsilon 5 (5'-gag tct aga gga atc caa cgt gga gga ttt a-3') and DNA pol epsilon 3 (5'-gag gaa ttc cta atg gcc cag ctg tgg gtt ctt-3') followed by cloning into the EcoRV and XbaI sites of pBD7. 5'epsilon and 3'epsilon contain cDNAs corresponding to amino acids 1-998 and 996-2287, respectively, of human DNA pol epsilon cloned into in pSK-BBV. p53 contains full-length murine p53 in the pBBV vector prepared from pGAL4-AD-p53 by excising a BamHI-BglII fragment and cloning this into the EcoRV site of pBBV. Full-length human DNA pol epsilon was amplified from MCF-7 cDNA using rTth-XL (Perkin Elmer) and oligonucleotides Pol epsilon 5 (5'-gag agg tac ccc acc ggc tcc atg tct ctg ag-3') and Pol epsilon 3 (5'-gag aga gtc gac cta atg gcc cag ctg tgg gtt ctt-3'). pCEP-DNA pol epsilon contains full-length human cDNA from DNA pol epsilon cloned into the KpnI and SalI sites of pCEP4 (Invitrogen). Full-length DNA pol epsilon for in vitro transcription/translation reactions was generated by PCR from pCEP-DNA pol epsilon with primers Pol epsilon 5'-XbaI (5'-gag atc tag aca acg gct cca tgt ctc tga g-3') and Pol epsilon 3'-XbaI (5'-gag atc tag act aat ggc cca gct gtg ggt t-3') using rTth-XL and subcloned into the XbaI site of pSK-BBV (generated by subcloning the HindIII-BglII fragment from pBBV into the HindIII and BamHI sites of pBluescript SKII+; Stratagene). Plasmids pCMVBamNeo, pCMVBamNeo-MDM2 and p53SN3 were obtained from B. Vogelstein.
###end p 10
###begin p 11
###xml 90 92 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c40">40</xref>
The 3C5.1 antibody to DNA pol epsilon for western blotting has been described previously (40). The MDM2-specific antibodies Ab-1 (IF2) and SMP14 were purchased from Oncogene Research Products and Santa Cruz Biotechnology, respectively. The anti-hemagglutinin (HA) antibody 12CA5 was purchased from Roche Molecular Biochemicals.
###end p 11
###begin title 12
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast two-hybrid analysis and construction of MDM2 deletion mutants
###end title 12
###begin p 13
###xml 451 454 445 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pst</italic>
###xml 513 516 507 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 522 525 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 740 743 734 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 750 753 744 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pst</italic>
###xml 811 812 805 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 817 818 811 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 854 855 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 860 861 854 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 866 867 860 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
###xml 937 942 <span type="species:ncbi:4932">yeast</span>
We utilised Clontech's Matchmaker system to screen a mouse T cell lymphoma library (ML4001AE) for MDM2-interacting clones. The same system was used for analysis of the interaction between the C-terminus of DNA pol epsilon and the various MDM2 deletion mutants. To generate C-terminal deletion mutants in pGAL4-DBD-MDM2, a stuffer fragment (5'-gag act cga gct gca ggt cga cgc ggc cgc ggt acc gca tgc ctg cag ctg gag gag a-3') was first cloned into the PstI site of this vector. The vector was then restricted with KpnI and NotI and, after purification, DNA was digested with ExoIII for varying periods of time, blunt-ended with Klenow DNA polymerase and religated. Recombinants containing MDM2 deletions were identified after digestion with EcoRI and PstI and sequenced. Transformants were grown overnight in trp-, leu- medium and then streaked onto a trp-, leu-, his- plate. Plates were placed at 30degreesC for 3 days and the growth of yeast monitored.
###end p 13
###begin title 14
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
In vitro binding assay
###end title 14
###begin p 15
###xml 94 96 94 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 409 411 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 501 509 485 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
MDM2 was expressed in XL-1 bacteria (Stratagene) from the pQE32-MDM2 construct, captured on Ni2+-agarose and washed with buffers B, C and D as described by the manufacturer (Qiagen). Prior to all binding reactions, protein captured on beads was run on a SDS-polyacrylamide gel and Coomassie blue stained to confirm that full-length MDM2, Delta1-49 MDM2 and Delta1-166 MDM2 were successfully purified on the Ni2+-agarose beads. An aliquot of 100 microl of washed beads was then mixed with 10 microl of in vitro translated protein (TNT; Promega) for 3 h at 30degreesC, followed by washing three times in wash buffer (20 mM HEPES, pH 7.9, 20% glycerol, 0.1 M KCl) supplemented with 75 mM imidazole. Beads were then resuspended in SDS-PAGE loading buffer and analysed by SDS-PAGE and fluorography.
###end p 15
###begin title 16
Immunoprecipitation and western blotting
###end title 16
###begin p 17
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c41">41</xref>
###xml 317 324 <span type="species:ncbi:3847">soybean</span>
###xml 1002 1007 <span type="species:ncbi:10090">mouse</span>
###xml 1011 1022 <span type="species:ncbi:3704">horseradish</span>
H1299 cells (ATCC clone CRL-5803) were grown and transfected with calcium phosphate as described previously (41). Transfected H1299 cells were then lysed in IP buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100, 0.5 mg/ml BSA, 1 mM PMSF and 1 microg/ml each pepstatin, leupeptin, aprotinin and soybean trypsin inhibitor; Roche Molecular Biochemicals), placed on ice for 10 min, clarified by centrifugation for 10 min and 1-5 mg protein incubated for 1 h at 4degreesC with 50 microl of protein G-Sepharose (Pharmacia). Beads were removed by centrifugation and the supernatant was then incubated with 1 microg SMP14 antibody or a control antibody of the same isotype for 1 h at 4degreesC, followed by 2 h at 4degreesC with 50 microl of protein G-Sepharose. Beads were washed three times in IP buffer and then resuspended in 30 microl of loading buffer prior to SDS-PAGE. Proteins were transferred to Hybond-ECL membrane, probed with antibodies 3C5.1 and IF2 and detected with anti-mouse Ig-horseradish peroxidase and Luminol (Renaissance; NEN).
###end p 17
###begin title 18
RESULTS
###end title 18
###begin title 19
###xml 46 51 <span type="species:ncbi:4932">yeast</span>
MDM2 interacts with DNA polymerase epsilon in yeast
###end title 19
###begin p 20
###xml 262 270 262 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c42">42</xref>
###xml 65 70 <span type="species:ncbi:4932">yeast</span>
###xml 207 212 <span type="species:ncbi:4932">yeast</span>
To identify novel candidate MDM2-binding proteins we performed a yeast two-hybrid screen using MDM2 as the bait. Numerous candidate clones were identified that appeared to specifically interact with MDM2 in yeast. These cDNAs were subsequently screened using an in vitro binding assay. Four clones were found to encode a peptide that clearly and reproducibly bound to MDM2 in this assay (M.T.Boyd, D.S.Haines and N.Vlatkovic, unpublished results). Sequence analysis of these revealed that each encoded a different protein, namely full-length p53, a C-terminal fragment of the 34 kDa subunit of TFIIE (42), the C-terminus of the catalytic subunit of DNA pol epsilon and a previously unidentified protein (M.T.Boyd, D.S.Haines and N.Vlatkovic, submitted for publication). This report focuses on characterisation of the interaction between MDM2 and DNA pol epsilon.
###end p 20
###begin p 21
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd508f1">1</xref>
###xml 135 136 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 141 142 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 310 311 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 316 317 304 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 322 323 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 417 418 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd508f1">1</xref>
###xml 87 92 <span type="species:ncbi:4932">yeast</span>
###xml 164 169 <span type="species:ncbi:4932">yeast</span>
Figure 1A shows that MDM2 interacts with the C-terminus of DNA pol epsilon. All of the yeast transformants were able to grow on the trp-, leu- plate but only those yeast that had been transfomed with MDM2 together with either the C-terminal DNA pol epsilon or p53 fusion constructs were able to grow on the trp-, leu-, his- plate. The region of DNA pol epsilon that was identified in this analysis is shown in Figure 1B.
###end p 21
###begin title 22
###xml 43 51 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
MDM2 interacts with DNA polymerase epsilon in vitro
###end title 22
###begin p 23
###xml 68 76 62 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 353 361 311 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 403 404 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd508f2">2</xref>
###xml 611 619 563 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 840 848 780 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 111 117 <span type="species:ncbi:10090">murine</span>
###xml 135 141 <span type="species:ncbi:10090">murine</span>
###xml 255 260 <span type="species:ncbi:9606">human</span>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 311 316 <span type="species:ncbi:9606">human</span>
###xml 761 767 <span type="species:ncbi:10090">murine</span>
###xml 772 777 <span type="species:ncbi:9606">human</span>
###xml 818 823 <span type="species:ncbi:9606">human</span>
We next tested the ability of MDM2 to interact with DNA pol epsilon in vitro. cDNAs encoding the C-terminus of murine DNA pol epsilon (murine 3'epsilon) (the same region present in the GAL4AD-DNA pol epsilon fusion construct), the corresponding region of human DNA pol epsilon (human 3'epsilon) and full-length human DNA pol epsilon were cloned into an in vitro transcription/translation vector. Figure 2 shows that all three forms of DNA pol epsilon bind to recombinant MDM2 (MDM2) prepared from XL-1 bacterial cells and not to protein prepared in the same manner from vector-transformed XL-1 bacteria (XL-1). In vitro synthesised p53 is also shown as a positive control for MDM2 binding. These results demonstrate that MDM2 can bind to the C-terminus of both murine and human DNA pol epsilon and also to full-length human DNA pol epsilon in vitro.
###end p 23
###begin title 24
MDM2 interacts with DNA polymerase epsilon in mammalian cells
###end title 24
###begin p 25
###xml 499 500 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd508f3">3</xref>
###xml 851 857 815 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">id est</italic>
We next wanted to determine whether MDM2 and full-length DNA pol epsilon could interact in mammalian cells. H1299 cells were transfected with constructs expressing either DNA pol epsilon or MDM2 or both as indicated. Following transfection, protein extracts were prepared and immunoprecipitations were performed with either an MDM2-specific antibody or with an isotype-matched control antibody. Western blots were then probed with either an antibody specific for MDM2 or for DNA pol epsilon. Figure 3A shows that after immunoprecipitation with the MDM2-specific antibody, DNA pol epsilon could be detected in extracts from DNA pol epsilon-transfected H1299 cells and in H1299 cells transfected with both MDM2 and DNA pol epsilon, but not in extracts from cells transfected with MDM2 alone. Note that we attempted to perform the reciprocal experiment, id est using an anti-DNA pol epsilon antibody for the immunoprecipitation step, but were thwarted by the presence of a non-specific precipitating protein that co-migrated with MDM2 and which cross-reacted with our secondary antibody (not shown). The ability to detect DNA pol epsilon in the extracts from DNA pol epsilon-transfected cells in the absense of transfected MDM2 is most likely due to the interaction of transfected DNA pol epsilon with endogenous MDM2 present in these cells. The amount of immunoprecipitated DNA pol epsilon was found to be greater in extracts from cells that had been transfected with both DNA pol epsilon and MDM2 expression constructs. This suggests that DNA pol epsilon is the limiting factor in detecting these MDM2-DNA pol epsilon complexes. DNA pol epsilon could not be detected in any of the extracts from the transfected cells that had been immunoprecipitated with an antibody of the same isotype but specific for a heterologous protein. These results demonstrate that MDM2 and DNA pol epsilon can form stable protein complexes in transfected cells.
###end p 25
###begin p 26
###xml 386 387 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd508f3">3</xref>
In order to determine whether MDM2 and DNA pol epsilon can form stable complexes in untransfected cells, we performed similar precipitation experiments with a HeLa cell nuclear extract. This extract contains an approximately10-fold enrichment of both MDM2 and DNA pol epsilon protein per microg total protein when compared with extracts prepared from unfractionated H1299 cells. Figure 3B shows that DNA pol epsilon can indeed be detected precipitating in a complex with MDM2 in this nuclear extract. As before, DNA pol epsilon could not be detected in immunoprecipitations performed with an isotype control antibody. These results suggest that DNA pol epsilon and MDM2 can form stable protein complexes in mammalian cells.
###end p 26
###begin title 27
Amino acids 50-166 of MDM2 are sufficient for binding to DNA polymerase epsilon
###end title 27
###begin p 28
###xml 334 335 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd508f4">4</xref>
###xml 567 568 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd508f4">4</xref>
###xml 571 573 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c41">41</xref>
###xml 248 253 <span type="species:ncbi:4932">yeast</span>
###xml 717 722 <span type="species:ncbi:4932">yeast</span>
To identify the region of MDM2 that is required for binding to the C-terminal region of DNA pol epsilon, we constructed a series of C-terminal deletion mutants of MDM2 in the pGAL4-DBD-MDM2 construct. Deletion mutants of MDM2 were transformed into yeast containing either pGAL4-AD-p53 or pGAL4-AD-DNA pol epsilon as indicated. Figure 4A demonstrates that an MDM2 deletion mutant containing only the first 166 amino acids of MDM2 is sufficient for interaction with DNA pol epsilon. As expected, this same mutant also retains the ability to interact with p53 (see Fig. 4A; 41). These results demonstrate that the first 166 amino acids of MDM2 are sufficient to interact with the C-terminal region of DNA pol epsilon in yeast.
###end p 28
###begin p 29
###xml 301 302 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd508f4">4</xref>
###xml 1052 1053 1004 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd508f4">4</xref>
###xml 1150 1158 1096 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 287 292 <span type="species:ncbi:4932">yeast</span>
###xml 333 339 <span type="species:ncbi:10090">murine</span>
###xml 462 467 <span type="species:ncbi:9606">human</span>
###xml 1070 1076 <span type="species:ncbi:10090">murine</span>
To confirm these results using a different system and to further define the DNA pol epsilon binding site on MDM2, two N-terminal deletion mutants of MDM2 were generated. The first mutant (Delta1-166) lacks the region of MDM2 that was found to be necessary for DNA pol epsilon binding in yeast. Figure 4B shows that the C-terminus of murine DNA pol epsilon binds to full-length MDM2 but not to the Delta1-166 mutant. Also shown are binding results for mutants of human DNA pol epsilon that express N- and C-terminal moieties of this molecule. These results indicate that the region of DNA pol epsilon that is necessary to bind to MDM2 is encoded within the C-terminal half of the molecule. Note that the background is higher for the N-terminal moiety of DNA pol epsilon and this may reflect a higher affinity of this portion of the molecule, perhaps because it contains the catalytic region, for the polyanionic bead matrix (agarose). The second MDM2 mutant (Delta1-49) lacks the first 49 amino acids of MDM2 (a region required for p53 binding). Figure 4C shows that the murine C-terminal region of DNA pol epsilon is able to bind to full-length MDM2 in vitro and also to Delta1-49. As expected, p53 does not bind to Delta1-49. Thus we conclude that the minimal DNA pol epsilon binding region of MDM2 is located between amino acids 50 and 166.
###end p 29
###begin title 30
DISCUSSION
###end title 30
###begin p 31
###xml 283 291 277 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 636 644 612 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 905 913 875 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 922 924 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c36">36</xref>
###xml 983 985 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c10">10</xref>
###xml 986 988 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c11">11</xref>
###xml 1000 1002 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c43">43</xref>
###xml 1305 1307 1269 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c44">44</xref>
###xml 1308 1310 1272 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c45">45</xref>
###xml 245 250 <span type="species:ncbi:4932">yeast</span>
###xml 614 619 <span type="species:ncbi:9606">human</span>
The pathways by which high level expression of MDM2 alters cellular growth control in a p53-independent manner are unclear. We report here the identification of a novel MDM2-binding protein, DNA pol epsilon. This interaction was identified in a yeast two-hybrid screen and confirmed in vitro and by co-immunoprecipitation. Our results beg the question what is the functional significance of an MDM2-DNA pol epsilon interaction? We have performed numerous experiments to address this, but have not detected any effect of either MDM2 upon DNA pol epsilon or vice versa. MDM2 does not alter the catalytic activity of human DNA pol epsilon in vitro (M.T.Boyd, Y.Li, S.Linn and N.Vlatkovic, unpublished results). This may not be surprising considering that the MDM2-binding region on DNA pol epsilon (the C-terminus) is not contained within the domain that is necessary for catalytic activity of the enzyme in in vitro assays (36). MDM2 can induce proteasome-mediated degradation of p53 (10,11) and Numb (43). Therefore, we also examined whether MDM2 could alter the level of DNA pol epsilon protein, but we found no evidence for this (M.T.Boyd, D.S.Haines and N.Vlatkovic, unpublished results). This is not the first example of an MDM2-binding protein that is not targeted for degradation by binding to MDM2 (44,45).
###end p 31
###begin p 32
###xml 202 209 202 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c24">24</xref>
###xml 251 254 251 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c24">24</xref>
###xml 269 274 269 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F-1</italic>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c46">46</xref>
###xml 508 510 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c47">47</xref>
###xml 511 513 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c48">48</xref>
###xml 553 555 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c34">34</xref>
###xml 849 851 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c38">38</xref>
###xml 1460 1462 1426 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c49">49</xref>
###xml 1867 1875 1833 1841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1902 1904 1864 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c50">50</xref>
###xml 1960 1963 1922 1925 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF</sup>
###xml 2088 2090 2050 2052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd508c51">51</xref>
###xml 391 396 <span type="species:ncbi:4932">yeast</span>
###xml 493 506 <span type="species:ncbi:4896">fission yeast</span>
###xml 546 551 <span type="species:ncbi:4932">yeast</span>
###xml 673 678 <span type="species:ncbi:4932">yeast</span>
###xml 831 836 <span type="species:ncbi:4932">yeast</span>
###xml 841 847 <span type="species:ncbi:9606">humans</span>
###xml 863 868 <span type="species:ncbi:4932">yeast</span>
###xml 1363 1368 <span type="species:ncbi:4932">yeast</span>
###xml 2312 2317 <span type="species:ncbi:4932">yeast</span>
What other clues are there to this question of function? It has been shown in a transgenic animal model that MDM2 overexpressing cells go through multiple rounds of DNA replication prior to cytokinesis in vivo (24). This phenotype is observed in both p53 null (24) and E2F-1 null (46) backgrounds. The effect appears to be due to the ability of MDM2 to compromise the S phase checkpoint. In yeast this checkpoint has been shown to be dependent upon the DNA polymerase-alpha-primase complex in fission yeast (47,48) and DNA pol epsilon in budding yeast (34). Moreover, the region of DNA pol epsilon that we have identified as binding to MDM2 overlaps with the region of the yeast gene that is known to be essential for the S phase checkpoint function. This region of DNA pol epsilon contains a zinc finger that is conserved between yeast and humans (38). However, yeast do not possess MDM2 nor do they possess p53. Since MDM2 is up-regulated in a p53-dependent manner during the DNA damage response, the normal function(s) of MDM2 is likely to be dependent upon such a response pathway. From this it seems possible that MDM2 might form part of an S phase checkpoint in metazoan cells and thus may couple the stress response to the normal S phase checkpoint machinery, namely DNA pol epsilon. Given that DNA pol epsilon appears to be dispensable as a polymerase in yeast, it has been suggested that it plays more of a structural role in the replication complex (49). Thus the interaction that we have identified might be part of a recruitment process for MDM2 such that MDM2 may mediate other effects upon the regulation of DNA synthesis. One could reconcile many of the p53-independent effects of MDM2 if it were recruited to the replication complex and activated DNA synthesis. It is noteworthy that RB has been shown to bind to and stimulate the catalytic activity (in vitro) of DNA polymerase alpha (50). In addition, it has been shown that p53, MDM2 and p19ARF co-localise to distinct nuclear structures and it has been proposed that these structures may be involved in DNA synthesis (51). Clearly there exists considerable uncertainty regarding the function of DNA pol epsilon, particularly in metazoans. Our studies provide evidence that MDM2 interacts with a region of DNA pol epsilon that is essential in yeast and which may well play an important role in the function of DNA pol epsilon in mammalian cells.
###end p 32
###begin title 33
Figures and Tables
###end title 33
###begin p 34
###xml 66 67 60 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 298 299 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 304 305 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 310 311 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 320 321 308 309 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 58 63 <span type="species:ncbi:4932">yeast</span>
###xml 69 74 <span type="species:ncbi:4932">Yeast</span>
###xml 176 181 <span type="species:ncbi:4932">yeast</span>
###xml 338 343 <span type="species:ncbi:9606">human</span>
###xml 412 417 <span type="species:ncbi:4932">yeast</span>
 MDM2 interacts with the C-terminus of DNA pol epsilon in yeast. (A) Yeast transformed with the indicated plasmids were grown on plates lacking the indicated amino acids. Only yeast containing plasmid constructs for MDM2 together with either p53 or the C-terminus of DNA pol epsilon grew on the trp-, leu-, his- plate. (B) Diagram of the human DNA pol epsilon catalytic subunit with the region identified in our yeast two-hybrid screen and conserved domains indicated.
###end p 34
###begin p 35
###xml 37 45 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 63 71 57 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 95 103 89 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 278 286 272 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 219 225 <span type="species:ncbi:10090">murine</span>
 MDM2 interacts with DNA pol epsilon in vitro. Results from an in vitro binding assay in which in vitro translated radiolabelled proteins were mixed with purified protein from XL-1 bacterial cells (XL-1) or recombinant murine MDM2 protein (MDM2). IVT indicates 10% of the input in vitro translated protein. Assays were performed in duplicate as shown.
###end p 35
###begin p 36
###xml 48 49 42 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 759 760 743 744 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
 MDM2 interacts with DNA pol epsilon in cells. (A) Immunoprecipitations using either an MDM2-specific antibody (SMP14) or a control antibody of the same isotype were performed on extracts of H1299 cells transfected with 10 microg of the indicated plasmid. Following immunoprecipitation and SDS-PAGE, western blot analysis was performed using antibodies specific for either DNA pol epsilon or MDM2 as indicated. The panels on the left are western blots of the protein extract used as the input for the immunoprecipitations probed with the indicated antibodies as for the panels on the right. Also shown is the signal obtained from the heavy chain of the immunoprecipitating antibody which indicates that approximately equal amounts of each were precipitated. (B) Immunoprecipitation and western blot analysis using HeLa cell nuclear extract essentially as described in (A).
###end p 36
###begin p 37
###xml 73 74 67 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 232 233 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 238 239 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 244 245 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 318 319 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 383 384 371 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 389 390 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 395 396 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 446 447 434 435 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 465 473 453 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 511 519 499 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 812 820 778 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 887 888 853 854 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 893 901 859 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 956 964 922 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 76 81 <span type="species:ncbi:4932">Yeast</span>
###xml 635 641 <span type="species:ncbi:10090">murine</span>
###xml 758 763 <span type="species:ncbi:9606">human</span>
###xml 993 999 <span type="species:ncbi:10090">murine</span>
 Amino acids 50-166 of MDM2 contain the DNA pol epsilon-binding region. (A) Yeast expressing, as indicated, pGAL4-AD-p53 or pGAL4-AD-DNA pol epsilon were transformed with various pGAL4-DBD-MDM2 deletion mutants. Colony growth on trp-, leu-, his- plates is indicated as + and background or no growth is indicated by -. bThese mutants displayed limited intrinsic ability to grow on trp-, leu-, his- plates in the presence of pGAL4-AD (not shown). (B) Results from an in vitro binding assay in which the indicated in vitro translated radiolabelled proteins were mixed with purified protein from XL-1 bacterial cells (XL-1) or recombinant murine MDM2 protein (MDM2) or Delta1-166. 5'epsilon and 3'epsilon contain amino acids 1-998 and 996-2287, respectively, of human DNA pol epsilon. IVT indicates 10% of the input in vitro translated protein. Assays were performed in duplicate as shown. (C) An in vitro binding assay was performed essentially as above with in vitro translated DNA pol epsilon (murine 3'epsilon) or p53 and purified protein from XL-1 bacterial cells (XL-1) or recombinant MDM2 protein (MDM2) or Delta1-49.
###end p 37
###begin title 38
ACKNOWLEDGEMENTS
###end title 38
###begin p 39
This work was supported in part by grants from the Breast Health Institute of Philadelphia (to M.T.B.), the W.W. Smith Charitable Trust (to M.T.B. and D.S.H.) and by NIH grants CA70165 (to D.S.H.) and GM30415 (to S.L.).
###end p 39
###begin title 40
REFERENCES
###end title 40

